

Neuropsychological and Clinical Variables Associated with Cognitive Trajectories in Patients with Alzheimer's Disease

Marianna Riello¹, Monica Moroni^{3,*}, Stefano Bovo³, Flavio Ragni³, Manuela Buganza¹, Raffaella Di Giacopo¹, Marco Chierici³, Lorenzo Gios⁴, Matteo Pardini^{5,6}, Federico Massa^{5,6}, Monica Dallabona⁷, Elisa Vanzetta⁷, Cristina Campi^{5,6}, Michele Piana^{5,6}, Sara Garbarino⁵, Manuela Marenco⁵, Venet Osmani³, Giuseppe Jurman³, Antonio Uccelli^{5,6}, Bruno Giometto^{1,2}

¹Neurology Unit, Provincial Health Services of Trento, Trento, Italy
 ²University of Trento, Trento, Italy
 ³Data Science for Health Unit, Fondazione Bruno Kessler, Trento, Italy
 ⁴TrentinoSalute4.0, Trento, Italy
 ⁵IRCCS Ospedale Policlinico San Martino, Genoa, Italy
 ⁶Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI) Università di Genova, Genoa, Italy
 ⁷Department of Mental Health, Division of Psychology, Provincial Health Services of Trento, Trento, Italy
 Correspondence*:

Monica Moroni mmoroni@fbk.eu

2 ABSTRACT

Background: The NeuroArtP3 (NET-2018-12366666) is a multicenter study funded by the Italian Ministry of Health. The aim of the project is to identify the prognostic trajectories of Alzheimer's disease (AD) through the application of artificial intelligence (AI). Only a few AI studies investigated the clinical variables associated with cognitive worsening in AD. We used Mini Mental State Examination (MMSE) scores as outcome to identify the factors associated with cognitive decline at follow up.

Methods: A sample of N=126 patients diagnosed with AD (MMSE >19) were followed during 3 9 10 years in 4 time-points: T0 for the baseline and T1, T2 and T3 for the years of follow-ups. Variables of interest included demographics: age, gender, education, occupation; measures of functional 11 ability: Activities of Daily Living (ADLs) and Instrumental (IADLs); clinical variables: presence 12 or absence of comorbidity with other pathologies, severity of dementia (Clinical Dementia 13 Rating Scale), behavioral symptoms; and the equivalent scores (ES) of cognitive tests. Logistic 14 regression, random forest and gradient boosting were applied on the baseline data to estimate 15 the MMSE scores (decline of at least >3 points) measured at T3. Patients were divided into 16 multiple splits using different model derivation (training) and validation (test) proportions, and the 17 optimization of the models was carried out through cross validation on the derivation subset only. 18 The models' predictive capabilities (balanced accuracy, AUC, AUPCR, F1 score and MCC) were 19 computed on the validation set only. To ensure the robustness of the results, the optimization 20

was repeated 10 times. A SHAP-type analysis was carried out to identify the predictive power ofindividual variables.

Results: The model predicted MMSE outcome at T3 with a mean AUC of 0.643. Model interpretability analysis revealed that the global cognitive state progression in AD patients is associated with: low spatial memory (Corsi block-tapping), verbal episodic long-term memory (Babcock's story recall) and working memory (Stroop Color) performances, the presence of hypertension, the absence of hypercholesterolemia, and functional skills inabilities at the IADL scores at baseline. **Conclusion**: This is the first AI study to predict cognitive trajectories of AD patients using routinely

collected clinical data, while at the same time providing explainability of factors contributing to these trajectories. Also, our study used the results of single cognitive tests as a measure of specific cognitive functions allowing for a finer-grained analysis of risk factors with respect to the other studies that have principally used aggregated scores obtained by short neuropsychological batteries. The outcomes of this work can aid prognostic interpretation of the clinical and cognitive variables associated with the initial phase of the disease towards personalized therapies.

36 Keywords: Alzheimer dementia, mild cognitive impairment, MMSE, machine learning, random forest, SHAP analysis

1 INTRODUCTION

Alzheimer's Dementia (AD) represents a major cause of disability and mortality for 44 million people 37 worldwide and this number is expected to triple as the population ages by 2050 (Lane et al., 2018). 38 Although AD is recognized by the World Health Organization as a global public health priority, the first 39 pharmacological treatments have not yet been accepted and introduced into guidelines by all the competent 40 agencies in the world. Also, despite the monoclonal antibodies, used to treat amyloid accumulation in 41 early AD, have recently received approval from American Food and Drug Administration (US-FDA), the 42 relationship between cognitive benefit and side effects is still controversial (Cummings et al., 2024). For 43 these reasons the identification of factors which might influence the cognitive trajectories of the disease 44 could be crucial for a preventive therapy sought for AD. 45 Clinical consensus is consistent in considering AD a syndrome characterized by a continuum of clinical 46 and biological phenomena rather than three distinct clinically defined entities known as preclinical AD, 47 mild cognitive impairment (MCI) and dementia (McKhann et al., 2011; Dubois et al., 2016; Jack Jr et al., 48 2018). More specifically, patients progress from normal cognition to MCI due to AD, and subsequently 49 experience an increase in the severity of AD dementia (mild, moderate, and severe) (Sperling et al., 2011). 50 However, accurate prediction of AD trajectories over time still remains a challenging task due to the 51 complicated characteristics of the disease progression. Within this continuous process, many factors might 52 present an additive effect on cognition contributing to AD cognitive worsening, but the interplay between 53 these variables is still not well understood. For example, despite the extensive evidence showing the 54 crucial role of amyloid in driving cognitive decline, this finding does not fully explain the complexity of 55 late-life cognitive deterioration (Jagust et al., 2023). In fact, due to the different combinations between 56 biomarker profiles and cognitive stages in which AD occurs, it is still unclear whether the cognitive deficit 57 is attributable to AD alone or to other potential comorbidities (Jack Jr et al., 2018). These includes early 58 life risk factors, such as years of education (Xu et al., 2016), and some midlife and later life components, 59 including brain injury (Li et al., 2017), hypertension (McGrath et al., 2017), diabetes (Yen et al., 2022), 60 depression (Singh-Manoux et al., 2017; Wang et al., 2018) and cerebrovascular diseases (Wang et al., 61 2018; Xia et al., 2020; Rundek et al., 2023; see also the 14 risk factors model by Livingston et al., 2024). 62

As the disease progresses, individuals with pathological evidence of AD, but cognitively normal, named 63 64 "preclinical AD" patients (Morris et al., 2009; Vos et al., 2013), might suffer from cognitive decline that is detectable by sensitive neuropsychological measures (Albert et al., 2011). In particular, cognitive tasks 65 66 assessing memory deficits as semantic, episodic memory and executive functions, might be sensitive in 67 predicting future clinical AD (Amieva et al., 2008; for reviews see review: Twamley et al., 2006; Salmon et al., 2012; Mortamais et al., 2017). According to these assumptions, it might be of great importance to 68 69 identify factors influencing the worsening of the disease and on which we can act promptly. 70 Artificial intelligence (AI) models might play a significant role in this context, due to their ability in 71 leveraging massive amounts of data and uncovering intricate patterns and relationships that might be 72 missed by traditional statistical methods. Several studies applied AI models on patients data to highlight 73 the role of different factors in AD diagnosis and progression, focusing mainly on neuroimaging data, such as structural Magnetic Resonance Imaging (MRI) (e.g. Zeng et al., 2018; Lahmiri et al., 2019), functional 74 MRI (fMRI) (e.g. Sheng et al., 2019), Positron Emission Tomography (PET) (e.g. Peng et al., 2019) and 75 Single-photon Emission Computerized Tomography (SPECT) (e.g. Segovia et al., 2010; for a review see 76 77 Tanveer et al., 2020). 78 In recent literature, most of the studies aimed at modeling AD progression used data based on standardized publicly available multimodal dataset (Kumar et al., 2021). Several recent studies applied AI to electronic 79 health records (EHRs) to predict AD progression showing the predictive value of neuropsychological data 80 on cognitive decline (Zhu et al., 2016; Fisher et al., 2019; Dansson et al., 2021). However, despite the use 81 82 of big dataset and highly accurate model performance, these studies did not explore the contribution of individual cognitive tests to the diagnostic outcome. For example, the brief neuropsychological assessment 83 named Alzheimer's Disease Assessment Scale (ADAS-Cog) (Rosen et al., 1984) included in several EHRs 84 might not be as predictive as the performance at individual cognitive tests used in in-depth cognitive 85 evaluation. In general, for precision medicine, it may be appropriate when the screening tests, such as the 86 Mini Mental State Examination (MMSE) (Folstein et al., 1975), are followed by a wider comprehensive 87 battery of tests, administered by expert neuropsychologists and measuring specific cognitive abilities 88 (Riello et al., 2021) as described by the European diagnostic workflow (Frisoni et al., 2024). The aim of 89 90 this study is to identify which factors are associated with worsening MMSE scores at 3-year follow-up, represented by demographic, clinical, functional and cognitive variables. The MMSE is one of the most 91 widely used screening tests in clinical practice to assess the global cognitive functioning, is used as an 92 indicator of dementia onset (Arevalo-Rodriguez et al., 2015; Riello et al., 2021) and can provide useful 93 data for the rate progression of the cognitive decline (Chow et al., 2006). We expect these results might 94 be useful for the realization of a personalized approach aiming to reduce cost, increase effectiveness of 95 disease treatment and optimize care. 96

2 MATERIALS AND METHODS

97 2.1 Data Collection

This is a multi-center, retrospective, observational study involving patients admitted to the local healthcare trust - Azienda Provinciale per i Servizi Sanitari (APSS) of Trento (Italy) and the IRCCS (Scientific Institute for Research, Hospitalization, and Healthcare) San Martino Hospital of Genoa (Italy). Data selected for this study was collected as part of the standard routine practice. The centers collected data from patients diagnosed with AD at MCI or early dementia stages, in accordance with established diagnostic criteria (Albert et al., 2011; McKhann et al., 2011), providing longitudinal follow-up from the diagnosis/recruitment (baseline). Data were therefore collected at different timepoints, namely at baseline visit (T0) and at three

subsequent follow-ups (FU) (at 12, 24 and 36 months, T1-T2-T3). Inclusion criteria were: (1) MMSE >19; 105 (2) Patients who received a diagnosis of AD between May 2006 and August 2020. All AD patients met 106 the criteria for probable AD with at least intermediate likelihood based on (Albert et al., 2011; McKhann 107 et al., 2011). In details, our patients (N=126) met the core clinical criteria (decline from previous level of 108 functioning, gradual onset over months, evidence of lower performance in one or more cognitive domains 109 with amnestic and non-amnestic presentations, not explained by delirium or other major neurodegenerative 110 or psychiatric disorders) and the presence of neuronal injury imaging data (data from structural MRI 111 and/or from [18F]FDG PET). Furthemore, 62.7% of patients was also considered at high likelihood of 112 AD since they presented positive amyloid biomarkers from Amyloid-PET with specific tracers and/or 113 cerebrospinal fluid (CSF) assessment of amyloid isoforms (A β 42/A β 40 ratio), also in accordance with 114 the proposed AT(N) research framework (Jack Jr et al., 2018). Variables of interest were decided on the 115 basis of the retrospective available data in the two centers. Data collected were grouped into the following 116 categories: (1) Demographic variables including: age, education, gender and working position; (2) Clinical 117 features: duration of the disease, family history for a group of diseases, presence or absence of habits 118 (alcohol and smoking self reported habits) in the past and at diagnosis, presence or absence of comorbidities 119 (hypertension, hypercholesterolemia, head trauma, diabetes, heart disease, liver disease, thyroid disease, 120 tumors, cerebrovascular disease) assessed by specialists according to the national guide-lines, severity of 121 dementia at the Clinical Dementia Rating Scale (CDR) (Morris, 1993), presence or absence of motor aspects 122 (falls, dysphagia, parkinsonism as apraxia or pyramidal signs), assessed by the neurologists involved in 123 124 the study through the neurological examination, presence or absence of behavioral symptoms (depression, apathy, hallucinations/delusions, aggression, disinhibition/inadequate behavior, specific sleep-wake rhythm 125 disorders) collected from the administration of the Neuropsychiatric Inventory (NPI; Cummings, 1997), 126 and pharmacological therapy; (3) measures of functional daily abilities evaluated by the Activities of Daily 127 Living (ADLs) (Katz et al., 1963) and Instrumental activities (IADLs; Lawton, 1969) and, (4) Cognitive 128 data: in the form of equivalent scores (ES) of the neuropsychological assessment covering the following 129 domains: general cognitive functioning measured by the MMSE and the Montreal Cognitive Assessment 130 (MoCA; Nasreddine et al., 2005); memory functions examined by the Forward Digit Span and the Corsi 131 132 block-tapping test (Monaco et al., 2013), the Rey Auditory Verbal Learning Test (RAVLT; Carlesimo et al., 1996) and the Babcock's Story Recall Test (BSRT; Novelli et al., 1986), language assessed by the semantic 133 verbal fluency test (Novelli et al., 1986), attention investigated by the Trail Making test A-B (Amodio et al., 134 2002), executive functions measured by the phonological verbal fluency test (Carlesimo et al., 1995) and 135 the Stroop Color and Word Test (SCWT; Barabrotto et al., 1998) and visuospatial abilities assessed by the 136 Clock Drawing Test (CDR; Cafarra et al., 2011). For additional information about the collected variables, 137 see Table S1. 138

139 2.2 Data Processing

The outcome variable, namely the presence of global cognitive impairment, was defined as a decrease of at least 3 points at the MMSE test score measured at the 3 years follow-up (Zhu et al., 2016).

142 Before being parsed by predictive models, the collected variables included in this study underwent a 143 common preprocessing phase. The first step was to remove variables with more than 30% of missing values,

144 no variability or with less than 10% of samples in the minority class. Features with a high proportion

145 of missing values, no variability or highly unbalanced, in fact, may not provide reliable information,

146 potentially introducing noise in the training process and limiting the overall performance of machine

- 147 learning models. For the remaining predictors, missing values were imputed with the median for numerical
- 148 variables, while for ordinal and categorical variables the most frequent value was used. ADL and IADL

149 scores were considered as fraction between the number of preserved and total number of tested activities.

150 According to this definition, ADL and IADL scores equal to 1 denote full independence, while values

151 smaller than 1 denote impairment in some functionalities with smaller values denoting greater impairment.

152 Before training the models, dataset variables were normalized using a quantile transformer, a min-max 153 scaler, an ordinal encoder and one hot encoder for numerical, binary, ordinal and categorical features

154 respectively.

155 2.3 Model Selection

To ensure optimal model selection, the full dataset was divided into a derivation (training) and validation (test) set. The training set was used to fit and optimize models, while the test set was employed to evaluate

158 models' performance.

159 Since the train-test split selection might influence results due to the intrinsic variability between different

subsets, multiple dataset partitions were used during the training process. This approach enabled the assessment of the robustness and stability of the tested algorithms: in fact, a model that performs consistently

162 well across different splits is more likely to be reliable and generalizable. Therefore, starting from the

162 whole dataset, four train-test splits were created using different proportions (60% - 40%, 70% - 30%, 80% -

- 164 20%, 90% 10%).
- 165 The performances of three machine learning models, namely Logistic regression (LR), Random Forest
- 166 (RF), and Gradient Boost (GB) were compared. LR is a classic supervised machine learning algorithm,167 mainly used for baseline binary classification problems where the goal is to predict the probability that an
- 168 instance belongs to a given class or not. The logistic function is used to describe the relationship between 169 the independent variables and the selected outcome. For each input, the model computes the probability
- 170 that a given input belongs to a certain class and then makes a prediction based on a chosen threshold.
- 171 RF consists of several independently trained decision trees that work together to provide a single output.

172 A random subset of the data set is used to build each tree to measure a random subset of features in each

173 partition. To make a prediction for a classification task, the algorithm aggregates the results of all trees by

voting. The combination of randomness and collaborative decision-making process, reduces the risk of
overfitting and provides stable and precise results.

176 GB is a powerful machine learning algorithm for classification and regression tasks. Similarly to RF, this is

177 a method that combines the predictions of multiple weak learners to create a single, more accurate strong 178 learner (i.e. ensemble learning)

178 learner (i.e. ensemble learning).

179 2.4 Parameters Optimization

The hyperparameters of each model were optimized by means of a randomized grid search procedure. 180 This begins by defining a set of possible values for each model's hyperparameters. Subsequently, a 181 combination of these values is randomly selected, and the model is trained and evaluated with and without 182 Synthetic Minority Over-sampling Technique (SMOTE; Chawla et al., 2002). SMOTE is a method used 183 to address class imbalance in ML datasets and operates by generating synthetic samples for the minority 184 class, thereby artificially balancing class distribution. This process was repeated 100 times for each model 185 using the Optuna hyperparameter optimization framework (Akiba et al., 2019) in a three-fold stratified 186 cross validation setting, repeated three times. The hyperparameter combination (with or without SMOTE) 187 with the highest Matthews Correlation Coefficient (MCC) score was selected (Chicco and Jurman, 2023). 188 189 MCC is a performance metric that takes into account both true positives (TP), true negatives (TN), false positives (FP) and false negatives (FN), providing a comprehensive evaluation of the quality of binary 190 classification. This entire process was repeated 10 times for each ML model and train-test split proportions, 191

Frontiers

192 for a total of 40 grid search procedures for each classifier. To evaluate the predictive performance of the 193 models several metrics were considered and computed on the test set, such as: balanced accuracy, the area 194 under the receiver operator characteristic curve (AUC), the area under the precision-recall curve (AUPRC),

195 the F1 score and the MCC.

196 2.5 Al Interpretability

197 To increase the interpretability of our results, Shapley Additive exPlanations (SHAP) method (Lundberg and Lee, 2017) was applied to the best performing model and train-test partition for each of the 10 198 199 iterations, to inspect the predictive power of individual variables. SHAP method increases the interpretability 200 deconstructing each prediction into a sum of individual contributions from each variable, emphasizing their influence both at the instance level and throughout the entire population split considered. For each 201 variable, higher SHAP values suggest a positive contribution to the model's prediction of MMSE decline at 202 203 T3. Moreover, to understand which feature contributed the most to models' prediction, for each of the ten runs a features importance ranking was performed, by sorting features for decreasing SHAP values., i.e. 204 for decreasing importance. Then, the features present consistently in the first ten positions in at least 60% 205 206 of the runs were selected as most informative.

3 RESULTS

207 3.1 Dataset and data preprocessing

Data collection resulted in a total of 126 patients: 25 patients from the APSS of Trento and 101 patients from the IRCCS Policlinico San Martino Hospital of Genoa.

210 During the preprocessing step the following variables were discarded: alcohol habit, head trauma, diabetes,

211 liver disease, falls, dysphagia, parkinsonism as apraxia or pyramidal signs, hallucinations/delusions,

212 aggression, disinhibition/inadequate behavior due to the low variability in the sample. At the same time,

213 among the cognitive tests, MoCA, Trail Making test A and B and Clock Drawing were eliminated due to

the high number of missing values.

215 After the dataset preprocessing steps, a total of 28 remaining features were selected for the upcoming

216 model training phase, comprising 4 demographic (gender, age at diagnosis, education and occupation), 217 12 clinical (including: smoke habit and CDR scores; comorbidities: hypertension, hypercholesterolemia,

217 12 chine at (including, shoke habit and CDK scores, comorbidities, hyperension, hyperensions and hebevieral

218 cardiopathy, thyroidopathy, tumors and cerebrovascular disease; family history of diseases and behavioral

- 219 symptoms: depression, apathy and sleep disorders), 2 functional variables (ADL, IADL) (see Table 1) and
- 220 10 cognitive scores of the neuropsychological battery (for a detailed list see Table 2).

Category	Variables	No. (%)
Demographic Characteristics	Female	70 (55.5%)
	Age at diagnosis	71.04 ± 7.10 years
	Education years	10.16 ± 4.37 years
Occupation	Elementary	24 (21.23%)
-	Medium-low	30 (26.54%)
	Medium	36 (31.85%)
	Medium-high	23 (20.35%)
	Major	13 (11.50%)
	N/A	13 (11.50%)
Smoking Status	Non-smoker	73 (56.34%)
-	Previous smoker	42 (33.33%)
	Current smoker	11 (8.73%)
CDR Scores	MCI (0)	101 (80.15%)
	Mild (0.5)	25 (19.84%)
	Moderate (1)	0
Comorbidities	Hypertension	65 (51.58%)
	Hypercholesterolemia	61 (48.41%)
	Cardiopathy	16 (12.69%)
	Thyroidopathy	19 (15.07%)
	Tumors	20 (15.87%)
	Cerebrovascular disease (Fazekas >1)	28 (22.22%)
Family History of Diseases	None	66 (52.38%)
	Dementia	50 (39.68%)
	Parkinson	5 (3.96%)
	Multiple sclerosis	1 (0.79%)
	Lateral amyotrophic sclerosis	0
	Cerebral tumors	0
	Psychiatric pathology	
	Other	6 (4.76%)
Behavioral Symptoms	Depression	74 (58.73%)
	Apathy	31 (24.60%)
	No sleep disorders	100 (79.36%)
	Sleep behavior disorder	2(1.58%)
	Insomnia	23 (20.35%)
Functional Abilities	ADLs (6/6)	0.98 ± 0.07
	IADLs (8/8)	0.88 ± 0.18

Table 1.	Demographic and	clinical variable	es at baseline	included in the	predictive model.
----------	-----------------	-------------------	----------------	-----------------	-------------------

No., number; SD, standard deviation; CDR, Clinical Dementia Rating Scale; MCI, mild cognitive impairment; ADLs/IADLs, Activities of Daily Living\Instrumental.

Variable	ES scores mean (±SD), patients no.
MMSE	25.91 (±2.65, n=126)
Digit span forward	2.76 (±1.34, n=126)
Corsi block-tapping test forward	1.72 (±1.28, n=125)
Immediate recall (RAVLT)	0.95 (±1.34, n=112)
Delayed recall (RAVLT)	0.76 (±1.24, n=113)
BSRT	0.87 (±1.25, n=112)
Semantic verbal fluency test	2.15 (±1.40, n=120)
Phonological verbal fluency	2.56 (±1.48, n=123)
SCWT: Color	2.21 (±1.32, n=98)
SCWT: Color-ColorWord	1.82 (±1.36, n=97)

Table 2. Neuropsychological variables at baseline included in the AI model.

ES, Equivalent Scores; SD, standard deviation; MMSE, Mini Mental State Examination; RAVL, Rey Auditory Verbal Learning Test; BSRT, Babcock's Story Recall Test; SCWT, Stroop Color Word Test

221 3.2 Predictive Variables

The aim of the current study was also to test the predictive power of different machine learning models (LR, RF and GB) to predict cognitive trajectories in AD patients, beyond highlighting the variables associated with a MMSE worsening at T3.

The model achieving the best performance and higher stability across all training sessions was RF with a 30% train-test split, with an AUC of 0.643 ± 0.04 (Fig. 1). This model was selected due to its small variability across iterations and train-test splits configurations, as shown in Table S2, and served as the reference for the interpretability analysis.

The SHAP analysis, performed to identify the most informative variables consistently present across 229 iterations (>60%), highlighted: 2 clinical, 1 functional and 3 cognitive variables with the highest predictive 230 impact at T3 (Fig. 2). Interestingly, the significant predictive variables affected cognitive performance 231 differently. Specifically, the decline of general cognitive abilities measured by MMSE in AD patients was 232 associated with the presence of hypertension and the absence of hypercholesterolemia, also, with impaired 233 functional abilities (IADL <1, i.e. at least one impaired functionality) and with low performances on the 234 following cognitive tests: the Corsi block-tapping test (ES <1), the BSRT (ES <1), and the SCWT (ES 235 236 <2).

4 **DISCUSSION**

This study investigated the best AI model to identify which variables, among a combination of demographic, clinical, functional and neuropsychological factors, potentially influence the risk of significant decline of global cognitive functioning, as measured by MMSE in AD patients. Our results demonstrated strong associations between clinical, functional and neuropsychological variables and the MMSE scores at 3 years FU. Patients suffering from hypertension experienced a decline in MMSE scores at T3. In addition, patients with significantly poorer performance on the Corsi block-tapping test, on the BSRT, and, on the SCWT, exhibited a more rapid cognitive deterioration. In contrast, patients with hypercholesterolemia



Figure 1. ROC curves showing the performance of the Random Forest (RF) classifier across selected test set sizes (10%, 20%, 30%, and 40%). The True Positive Rate is plotted against the False Positive Rate for each test size, with the Area Under the Curve (AUC) illustrating classifier effectiveness. Blue line represents the mean ROC, the shaded gray area indicates variability across iterations, and the red dashed line corresponds to the line of no-discrimination (AUC = 0.5).

and preserved functional instrumental abilities (IADL=1, i.e. full independence) at baseline did not show
cognitive worsening. These findings suggest that some variables may serve as predictors of global cognitive
trajectories over time, acting either as a risk or a protective factor for cognitive abilities.

In recent literature, several studies applied AI techniques to investigate which variables influence the 247 worsening of cognitive performance over time in AD patients using clinical data. In particular, Zhu and 248 colleagues 2016, compared the performance of different machine learning algorithms to predict the decline 249 250 of MMSE scores at 2-years FU. Their dataset included demographic variables, genetic information and neuropsychological composite measures of memory and executive functions. Later, Fisher and colleagues 251 2019 examined which variables, including laboratory tests, clinical, demographic and genetic data, together 252 253 with cognitive test results, predict cognitive worsening in MCI or AD patients over an 18- month period. 254 More recently, Dansson et al. 2021 applied similar techniques to model patients' cognitive trajectories 255 at 2 and 4 years, by including demographic variables, biochemical-markers (proteins, lipids, hormones), 256 the CSF (A β 42 and A β 40) and neuroimaging data (MRI and FDG-PET) as well as a wide range of 257 neuropsychological scores.

Compared to the existing literature, this is the first study predicting cognitive trajectories of AD patients using clinical data only, while at the same time providing explainability of factors contributing to these trajectories. The implemented SHAP analysis, in fact, allows not only to highlight the most important features associated with cognitive decline, but also to unveil how feature values contribute to model prediction. In particular, when applied to neuropsychological tests and IADL, this process might allow the detection of plausible test-specific cut-offs indicative of cognitive decline.

Furthermore, the retrospective dataset considered in the current work provides some crucial advantages compared to publicly available repositories used in previous studies. As an example, the close collaboration with the data collection team allowed for the resolution of several data provenance issues that typically arise during data analysis, such as inconsistencies across features or the detection of outliers, thereby maximizing the amount of usable data. Indeed, the literature indicates that potentially informative electronic public datasets are susceptible to inaccuracies (Vyas et al., 2021). In addition, to assess patients' cognitive profile, scores from individual neuropsychological tests were considered. Compared to aggregated scores extracted

271 from short neuropsychological test batteries, this potentially allows for a finer-grained analysis of risk272 factors.

Our study identified several neuropsychological variables that predict significant declines in generalcognitive functioning over time. Specifically, low baseline performance in visuo-spatial short-term working



Figure 2. Shapley Additive exPlanations (SHAP) analysis results for the best-performing model (Random Forest, using a 70-30% train-test split). Features that consistently ranked within the top ten across at least 60% of runs are reported. For categorical variables (e.g. hypertension and hypercholesterolemia), beeswarm plots are shown, where each point represents a SHAP value for a feature and an individual observation. Blue points indicate low variable values, while red points indicate high values. For continuous variables (e.g. IADL score, Corsi block tapping test, Babcock story recall, and Stroop color-word test), dependence plots are presented, with each point representing a feature score for an individual participant. Higher SHAP values suggest a positive contribution to the model's prediction of MMSE decline at T3.

275 memory, assessed via the Corsi block-tapping test, long-term verbal memory skills measured by the BSRT, 276 and executive function related to the inhibition of cognitive interference, evaluated through the SCWT, were 277 all associated with deterioration at T3. The role of memory disorders as prodromal symptoms of AD has 278 been well established (Amieva et al.) 2008; Grober et al.) 2008), therefore the presence of such impairments 279 at disease onset might be considered a foregone conclusion. Cognitive assessment of visuo-spatial and 280 verbal memory is routinely employed in clinical settings to evaluate degenerative diseases. The Corsi 281 block-tapping test has been already recognized as a crucial test for the diagnosis of AD differentiating patients from controls at moderate stages (Guariglia, 2007). Additionally, the story recall test has been
shown to predict progression to dementia in patients with MCI (Park et al., 2017), while the Stroop test is
commonly used to differentiate healthy aging from early AD in elderly populations (Hutchison et al., 2010).
Our results align with existing literature, which indicates that episodic memory and executive functions
are the cognitive domains most susceptible to deterioration in patients with early AD (for a review see
Twamley et al., 2006; Salmon et al., 2012; Mortmais et al., 2017).

Moreover, our results corroborate the significance of neuropsychological data in predicting global cognitive 288 289 deterioration. Despite the heterogeneity of the variables studied, Zhu 2016 emphasized the importance of 290 executive (ADNI-EF) and memory (ADNI-MEM) components, while Fisher 2019 reported the significance 291 of cognitive trials based on immediate and delayed recall items belonging to the MMSE and to the ADAS 292 battery. Dansson 2021 identifies the ADAS and the TMT cognitive tests as strong predictors of cognitive 293 decline. However, none of these studies reported the significance of the spatial memory test (Corsi block-294 tapping test), nor the verbal memory test for structured material (BSRT) or the ability of inhibiting cognitive 295 interference (SCWT) in the prediction, as we have found. Nevertheless, we must highlight that there is a lack of uniformity in the neuropsychological data employed in the cited literature; for instance, Zhu 296 297 2016 utilized cognitive scores as composite variables (e.g., ADNI-EF and MEM), while Fisher 2019 and 298 Dansson 2021 relied on short neuropsychological batteries like the ADAS, which did not include the Corsi 299 span or Stroop tests.

300 Our analysis indicates that the baseline assessment of cognitive functions can predict global cognitive 301 decline over time, a conclusion supported also by other studies applying AI algorithms to clinical data 302 from AD patients (Zhu et al., 2016; Fisher et al., 2019; Dansson et al., 2021). Conversely, the existing 303 literature largely overlooks the association between spatial memory and cognitive deterioration, with few 304 studies incorporating spatial memory assessments. Among the multiple studies considered in the reviews 305 by Twamley et al. (2006) and Salmon et al. (2012), only one included the Corsi span test, while Mortamais et al. (2017) cited only two studies featuring it. In light of our findings, we believe it would be important 306 to include the span space score in baseline neuropsychological assessments for MCI patients with AD 307 308 biomarkers, as it may enhance the prediction of cognitive progression.

309 Regarding clinical comorbidities, the present study highlighted the association between the presence of hypertension and cognitive decline, measured as a drop of the MMSE score. Conversely, an opposite pattern 310 was found for hypercholesterolemia, which might serve as a protective factor. The presence of hypertension 311 is consistently related with cognitive decline and increased risk of dementia (Tzourio et al., 1999; McGrath 312 et al., 2017). However, few studies found an opposite pattern (Wysocki et al., 2012; Streit et al., 2019), 313 suggesting that the association between blood pressure and brain cognitive functions is intricate and might 314 be modulated by study-specific factors, such as study design, population characteristics, and the specific 315 316 cognitive domains assessed (Iadecola et al., 2016; Sierra, 2020). Our dataset does not allow to inspect this issue in greater detail, thus further research will be required to clarify the role of hypertension in cognitive 317 function among elderly individuals. 318 Elevated cholesterol levels are a major risk factor for cardiovascular disease, but their role in late-life 319

Elevated cholesterol levels are a major risk factor for cardiovascular disease, but their role in late-life cognitive function, dementia and cognitive decline is less clear. For example, Liu and collaborators 2021 found that long-term increases in higher total cholesterol and non-high density lipoprotein cholesterol levels were substantially associated with decreased risks of global cognitive and memory function decline. More precisely, when measured in late-life, elevated cholesterol levels show no association with a worsening of cognitive functions, or even an inverse relationship (van Vliet, 2012). Cholesterol, crucially, is an important component of nerve cell membranes and participates in the metabolic activities of nerve cells, it is essential for the formation and maturation of synapses and plays an important role in the regulation of signal transduction through its function as a component of the cell membrane (van Vliet, 2012). Furthermore,
cholesterol stores a large amount of energy, which can provide sustained energy to the brain, which is
the most energy-consuming organ of the body (Steiner, 2020). Therefore, the role of cholesterol in brain
protection might be different from its role in cardiovascular diseases.

Lastly, the link between functional variables and cognitive decline in older adults has not yet been 331 fully elucidated in the literature. Instrumental activities included in the IADLs questionnaire involve 332 skills requiring the recruitment of multiple cognitive processes (e.g. houseworks, managing medications 333 and finances, driving), and thus more complex than basic self-care activities measured by the ADLs 334 guestionnaires. Limited functionality in IADLs were found in literature to be predictive of dementia (Pérès 335 et al., 2008), even in individuals with normal cognitive performance at baseline (Di Carlo et al., 2007). The 336 SHAP analysis confirms that even a subtle decline in IADLs, restricted to a single instrumental activity 337 (IADL < 1), might be predictive of significant worsening in cognitive abilities. 338

Despite these encouraging findings, it is important from a methodological viewpoint to make some 339 considerations. First, while the sample size of the current study is sufficient to achieve robust and 340 reproducible results, it might not ensure the generalizability of the model to external data. Additionally, 341 as our dataset is derived from two Italian hospitals, it may not fully represent the broader AD population, 342 potentially limiting the model's applicability to different clinical settings. Second, the filtering process 343 adopted in this study, while effective in reducing the total number of features and inconsistencies, may 344 have led to the exclusion of potentially informative variables due to strict thresholds for missing values, 345 346 data variability, and class imbalance. This could limit the model's ability to capture subtle but clinically relevant patterns. Lastly, further analyses could be designed to try to enhance model performance, such 347 as different data preprocessing techniques (different handling of missing values and normalization) or 348 ensemble methods to combine predictions from multiple diverse machine learning algorithms. 349

5 CONCLUSIONS

Our findings highlight the clinical and cognitive variables assessed at baseline that contribute to the 350 deterioration of overall cognitive function or serve as protective factors. Identifying contributing factors of 351 352 cognitive decline along the AD continuum is essential for monitoring clinical progression and evaluating the efficacy of treatments to slow or preserve cognitive decline (GUIDANCE, 2018; Livingston et al., 353 2024). These results emphasize the importance of examining specific comorbidities, targeted cognitive 354 355 domains, and impairments in instrumental activities of daily living (IADL), in addition to broader cognitive abilities, in both healthy and AD older adults. These insights are fundamental for tailoring 356 pharmacological treatments with respect to comorbidities and for developing potential rehabilitation 357 358 intervention focused on specific cognitive domains. Regarding limitations, further research is required to evaluate the generalizability of our model across different patient populations, despite the study's 359 multicentric nature. Furthermore, inclusion of genetic and imaging data might have improved the 360 performance of the model, at the expense of added complexity. 361

CONFLICT OF INTEREST STATEMENT

362 FM received speaker honoraria from Roche Diagnostics S.p.A and Eli Lilly S.p.A.

363 The authors declare that the research was conducted in the absence of any commercial or financial 364 relationships that could be construed as a potential conflict of interest.

AUTHOR CONTRIBUTIONS

Conceptualization: MB, RDG, VO, GJ, LG, M. Pardini, FM, AU, BG; Funding acquisition, Project
administration: M. Marenco, LG, RM; Formal analysis, Investigation, Methodology, Software, Data entry:
MR, M. Moroni, MC, FR, SB, MD, EV, CC, M. Piana, SG; Supervision, Writing – review and editing:
MR, M. Moroni, FR, SB, VO, MB, RDG, M. Pardini, FM

FUNDING

The author(s) declare financial support was received for the research, authorship, and/or publication of 369 this article. This research was co-funded by the Italian Ministry of Health, grant number NET-2018-370 12366666 NeuroArtP3, and by FRA2022/DINOGMI from the Department of Neuroscience, Rehabilitation, 371 Ophthalmology, Genetics, Maternal and Child Health, University of Genoa. The funders had no role 372 in study design, data collection and analysis, decision to publish, or preparation of the manuscript. FM 373 is funded by the Ministry of University and Research (MUR), National Recovery and Resilience Plan 374 (NRRP), project MNESYS (PE0000006) - A Multiscale integrated approach to the study of the nervous 375 system in health and disease (DN. 1553 11.10.2022). 376

DATA AVAILABILITY STATEMENT

The informed consent obtained from participants did not include authorization for data sharing.Consequently, the supporting data cannot be made publicly available.

ETHICS STATEMENT

The study was approved by the Locals Ethics Committees (Ethics Committee of Azienda Provinciale per i Servizi Sanitari of Trento (Rep. Int. 12221 N° 7/2022 of 13/07/2022) and Ethics Committee of Liguria Region (N° 373/2021 . DB id 11999). The protocol for this study refers to the NeuroArtP3 (NET-2018-12366666) project. The NeuroArtP3 project is a four-year multi-centre study aimed at promoting the collaboration between clinical and computational centres operating in the field of neurology, co-founded by the Italian Ministry of Health. Written informed consent was obtained from every participant and all assessments were performed according to national and international guidelines.

REFERENCES

- Akiba, T., Sano, S., Yanase, T., Ohta, T., and Koyama, M. (2019). Optuna: A next-generation
 hyperparameter optimization framework. In *Proceedings of the 25th ACM SIGKDD international conference on knowledge discovery & data mining*. 2623–2631
- Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., et al. (2011). The
 diagnosis of mild cognitive impairment due to alzheimer's disease: recommendations from the national
 institute on aging-alzheimer's association workgroups on diagnostic guidelines for alzheimer's disease.
 Alzheimer's & dementia 7, 270–279
- Amieva, H., Le Goff, M., Millet, X., Orgogozo, J. M., Pérès, K., Barberger-Gateau, P., et al. (2008).
 Prodromal alzheimer's disease: successive emergence of the clinical symptoms. *Annals of Neurology:*
- 395 *Official Journal of the American Neurological Association and the Child Neurology Society* 64, 492–498
- 396 Amodio, P., Wenin, H., Del Piccolo, F., Mapelli, D., Montagnese, S., Pellegrini, A., et al. (2002). Variability
- 397 of trail making test, symbol digit test and line trait test in normal people. a normative study taking into

398 399	account age-dependent decline and sociobiological variables. <i>Aging clinical and experimental research</i> 14, 117–131
400	Arevalo-Rodriguez, I., Smailagic, N., i Figuls, M. R., Ciapponi, A., Sanchez-Perez, E., Giannakou, A.,
401	et al. (2015). Mini-mental state examination (mmse) for the detection of alzheimer's disease and other
402	dementias in people with mild cognitive impairment (mci). Cochrane database of systematic reviews
403	Barbarotto, R., Laiacona, M., Frosio, R., Vecchio, M., Farinato, A., and Capitani, E. (1998). A normative
404 405	study on visual reaction times and two stroop colour-word tests. <i>The Italian Journal of Neurological</i> Sciences 19, 161–170
406	Caffarra P. Gardini S. Zonato F. Concari I. Dieci F. Copelli S. et al. (2011). Italian norms for the
407	freedman version of the clock drawing test. <i>Journal of Clinical and Experimental Neuropsychology</i> 33,
408	982–988
409	Carlesimo, G., Caltagirone, C., Gainotti, G., Fadda, L., Gallassi, R., Lorusso, S., et al. (1996). The
410	mental deterioration battery: normative data, diagnostic reliability and qualitative analyses of cognitive
411	impairment. European neurology 36, 378–384
412	Carlesimo, G. A., Sabbadini, M., Fadda, L., and Caltagirone, C. (1995). Forgetting from long-term memory
413	in dementia and pure amnesia: Role of task, delay of assessment and aetiology of cerebral damage.
414	Chaula N.V. Bouwer K.W. Hell, L.O. and Kagelmayer W.B. (2002). Smotel supthatic minority
415 416	over-sampling technique. <i>Journal of artificial intelligence research</i> 16, 321–357
417	Chicco, D. and Jurman, G. (2023). The matthews correlation coefficient (mcc) should replace the roc auc
418	as the standard metric for assessing binary classification. BioData Mining 16, 4
419 420	Chow, T. W., Hynan, L. S., and Lipton, A. M. (2006). Mmse scores decline at a greater rate in frontotemporal degeneration than in ad. <i>Dementia and geriatric cognitive disorders</i> 22, 194–199
421	Cummings, J., Osse, A. M. L., Cammann, D., Powell, J., and Chen, J. (2024). Anti-amyloid monoclonal
422	antibodies for the treatment of alzheimer's disease. BioDrugs 38, 5-22
423	Cummings, J. L. (1997). The neuropsychiatric inventory: assessing psychopathology in dementia patients.
424	Neurology 48, 10S–16S
425	Dansson, H. V., Stempfle, L., Egilsdóttir, H., Schliep, A., Portelius, E., Blennow, K., et al. (2021).
426	Predicting progression and cognitive decline in amyloid-positive patients with alzheimer's disease.
427	Alzheimer's Kesearch & Therapy 13, 1–16
428 420	DI Carlo, A., Lamassa, M., Baldereschi, M., Inzitari, M., Scarato, E., Farchi, G., et al. (2007). Cind and mei in the italian elderly: frequency vascular risk factors, progression to dementia. <i>Neurology</i> 68

- and mci in the italian elderly: frequency, vascular risk factors, progression to dementia. *Neurology* 68,
 1909–1916
- Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., et al. (2016). Preclinical
 alzheimer's disease: definition, natural history, and diagnostic criteria. *Alzheimer's & Dementia* 12,
 292–323
- Fisher, C. K., Smith, A. M., and Walsh, J. R. (2019). Machine learning for comprehensive forecasting of
 alzheimer's disease progression. *Scientific reports* 9, 13622
- Folstein, M. F., Folstein, S. E., and McHugh, P. R. (1975). "mini-mental state": a practical method for
 grading the cognitive state of patients for the clinician. *Journal of psychiatric research* 12, 189–198
- 438 Frisoni, G. B., Festari, C., Massa, F., Ramusino, M. C., Orini, S., Aarsland, D., et al. (2024). European

439 intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders. *The* 440 *Lancet Neurology* 23, 302–312

- Grober, E., Hall, C. B., Lipton, R. B., Zonderman, A. B., Resnick, S. M., and Kawas, C. (2008). Memory
 impairment, executive dysfunction, and intellectual decline in preclinical alzheimer's disease. *Journal of the International Neuropsychological Society* 14, 266–278
- Guariglia, C. C. (2007). Spatial working memory in alzheimer's disease: A study using the corsi blocktapping test. *Dementia & neuropsychologia* 1, 392–395
- GUIDANCE, D. (2018). Early alzheimer's disease: Developing drugs for treatment. *Center for Biologics Evaluation and Research (CBER)*
- Hutchison, K. A., Balota, D. A., and Ducheck, J. M. (2010). The utility of stroop task switching as a
 marker for early-stage alzheimer's disease. *Psychology and aging* 25, 545
- Iadecola, C., Yaffe, K., Biller, J., Bratzke, L. C., Faraci, F. M., Gorelick, P. B., et al. (2016). Impact
 of hypertension on cognitive function: a scientific statement from the american heart association. *Hypertension* 68, e67–e94
- Jack Jr, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., et al. (2018). Niaaa research framework: toward a biological definition of alzheimer's disease. *Alzheimer's & dementia*14, 535–562
- 456 Jagust, W. J., Teunissen, C. E., and DeCarli, C. (2023). The complex pathway between amyloid β and 457 cognition: implications for therapy. *The Lancet Neurology* 22, 847–857
- Katz, S., Ford, A. B., Moskowitz, R. W., Jackson, B. A., and Jaffe, M. W. (1963). Studies of illness in
 the aged: the index of adl: a standardized measure of biological and psychosocial function. *jama* 185,
 914–919
- Kumar, S., Oh, I., Schindler, S., Lai, A. M., Payne, P. R., and Gupta, A. (2021). Machine learning for
 modeling the progression of alzheimer disease dementia using clinical data: a systematic literature
 review. *JAMIA open* 4, 00ab052
- Lahmiri, S. and Shmuel, A. (2019). Performance of machine learning methods applied to structural mri
 and adas cognitive scores in diagnosing alzheimer's disease. *Biomedical Signal Processing and Control*52, 414–419
- Lane, C. A., Hardy, J., and Schott, J. M. (2018). Alzheimer's disease. *European journal of neurology* 25, 59–70
- Lawton, M. (1969). Assessment of older people; self-maintaining and instrumental activites of dialy living.
 Gerontologist 9, 279–286
- Li, Y., Li, Y., Li, X., Zhang, S., Zhao, J., Zhu, X., et al. (2017). Head injury as a risk factor for dementia
 and alzheimer's disease: a systematic review and meta-analysis of 32 observational studies. *PloS one* 12, e0169650
- Liu, H., Zou, L., Zhou, R., Zhang, M., Gu, S., Zheng, J., et al. (2021). Long-term increase in cholesterol
 is associated with better cognitive function: evidence from a longitudinal study. *Frontiers in Aging Neuroscience* 13, 691423
- Livingston, G., Huntley, J., Liu, K. Y., Costafreda, S. G., Selbæk, G., Alladi, S., et al. (2024). Dementia
 prevention, intervention, and care: 2024 report of the lancet standing commission. *The Lancet* 404,
 572–628
- 480 Lundberg, S. M. and Lee, S.-I. (2017). A unified approach to interpreting model predictions. In Proceedings
- 481 *of the 31st International Conference on Neural Information Processing Systems* (Red Hook, NY, USA:
 482 Curran Associates Inc.), NIPS'17, 4768–4777
- McGrath, E. R., Beiser, A. S., DeCarli, C., Plourde, K. L., Vasan, R. S., Greenberg, S. M., et al. (2017).
 Blood pressure from mid-to late life and risk of incident dementia. *Neurology* 89, 2447–2454

- McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack Jr, C. R., Kawas, C. H., et al. (2011).
 The diagnosis of dementia due to alzheimer's disease: Recommendations from the national institute on
 aging-alzheimer's association workgroups on diagnostic guidelines for alzheimer's disease. *Alzheimer's & dementia* 7, 263–269
- Monaco, M., Costa, A., Caltagirone, C., and Carlesimo, G. A. (2013). Forward and backward span
 for verbal and visuo-spatial data: standardization and normative data from an italian adult population. *Neurological Sciences* 34, 749–754
- Morris, J. C. (1993). The clinical dementia rating (cdr) current version and scoring rules. *Neurology* 43, 2412–2412
- Morris, J. C., Roe, C. M., Grant, E. A., Head, D., Storandt, M., Goate, A. M., et al. (2009). Pittsburgh
 compound b imaging and prediction of progression from cognitive normality to symptomatic alzheimer
 disease. *Archives of neurology* 66, 1469–1475
- Mortamais, M., Ash, J. A., Harrison, J., Kaye, J., Kramer, J., Randolph, C., et al. (2017). Detecting
 cognitive changes in preclinical alzheimer's disease: A review of its feasibility. *Alzheimer's & dementia*13, 468–492
- Nasreddine, Z. S., Phillips, N. A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., et al. (2005).
 The montreal cognitive assessment, moca: a brief screening tool for mild cognitive impairment. *Journal of the American Geriatrics Society* 53, 695–699
- Novelli, G., Papagno, C., Capitani, E., Laiacona, M., et al. (1986). Tre test clinici di memoria verbale a
 lungo termine: taratura su soggetti normali. *Archivio di psicologia, neurologia e psichiatria*
- Park, J.-H., Park, H., Sohn, S. W., Kim, S., and Park, K. W. (2017). Memory performance on the story recall
 test and prediction of cognitive dysfunction progression in mild cognitive impairment and alzheimer's
 dementia. *Geriatrics & gerontology international* 17, 1603–1609
- Peng, J., Zhu, X., Wang, Y., An, L., and Shen, D. (2019). Structured sparsity regularized multiple kernel
 learning for alzheimer's disease diagnosis. *Pattern recognition* 88, 370–382
- 510 Pérès, K., Helmer, C., Amieva, H., Orgogozo, J.-M., Rouch, I., Dartigues, J.-F., et al. (2008). Natural
- 511 history of decline in instrumental activities of daily living performance over the 10 years preceding the
- clinical diagnosis of dementia: a prospective population-based study. *Journal of the American Geriatrics Society* 56, 37–44
- Riello, M., Rusconi, E., and Treccani, B. (2021). The role of brief global cognitive tests and
 neuropsychological expertise in the detection and differential diagnosis of dementia. *Frontiers in aging neuroscience* 13, 648310
- Rosen, W. G., Mohs, R. C., and Davis, K. L. (1984). A new rating scale for alzheimer's disease. *The American journal of psychiatry* 141, 1356–1364
- Rundek, T., Tolea, M., Ariko, T., Fagerli, E. A., and Camargo, C. J. (2023). Vascular cognitive impairment
 (vci). *Neurotherapeutics* 19, 68–88
- Salmon, D. P. (2012). Neuropsychological features of mild cognitive impairment and preclinical alzheimer's
 disease. *Behavioral neurobiology of aging*, 187–212
- Segovia, F., Górriz, J., Ramírez, J., Salas-González, D., Álvarez, I., López, M., et al. (2010). Classification
 of functional brain images using a gmm-based multi-variate approach. *Neuroscience Letters* 474, 58–62
- Sheng, J., Wang, B., Zhang, Q., Liu, Q., Ma, Y., Liu, W., et al. (2019). A novel joint hcpmmp method for
 automatically classifying alzheimer's and different stage mci patients. *Behavioural brain research* 365,
 210–221
- 528 Sierra, C. (2020). Hypertension and the risk of dementia. Frontiers in cardiovascular medicine 7, 5

529	Singh-Manoux, A., Dugravot, A., Fournier, A., Abell, J., Ebmeier, K., Kivimäki, M., et al. (2017).
530	Trajectories of depressive symptoms before diagnosis of dementia: a 28-year follow-up study. JAMA
531	psychiatry 74, 712–718

Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., et al. (2011). Toward
defining the preclinical stages of alzheimer's disease: Recommendations from the national institute on
aging-alzheimer's association workgroups on diagnostic guidelines for alzheimer's disease. *Alzheimer's & dementia* 7, 280–292

- Steiner, P. (2020). Brain fuel utilization in the developing brain. *Annals of Nutrition and Metabolism* 75,
 8–18
- Streit, S., Poortvliet, R. K., den Elzen, W. P., Blom, J. W., and Gussekloo, J. (2019). Systolic blood pressure
 and cognitive decline in older adults with hypertension. *The Annals of Family Medicine* 17, 100–107
- Tanveer, M., Richhariya, B., Khan, R. U., Rashid, A. H., Khanna, P., Prasad, M., et al. (2020). Machine
 learning techniques for the diagnosis of alzheimer's disease: A review. ACM Transactions on Multimedia *Computing, Communications, and Applications (TOMM)* 16, 1–35
- Twamley, E. W., Ropacki, S. A. L., and Bondi, M. W. (2006). Neuropsychological and neuroimaging
 changes in preclinical alzheimer's disease. *Journal of the International Neuropsychological Society* 12,
 707–735
- Tzourio, C., Dufouil, C., Ducimetière, P., and Alpérovitch, A. (1999). Cognitive decline in individuals
 with high blood pressure: a longitudinal study in the elderly. *Neurology* 53, 1948–1948
- van Vliet, P. (2012). Cholesterol and late-life cognitive decline. *Journal of Alzheimer's Disease* 30,
 \$147-\$162
- Vos, S. J., Xiong, C., Visser, P. J., Jasielec, M. S., Hassenstab, J., Grant, E. A., et al. (2013). Preclinical
 alzheimer's disease and its outcome: a longitudinal cohort study. *The Lancet Neurology* 12, 957–965
- Vyas, A., Aisopos, F., Vidal, M.-E., Garrard, P., and Paliouras, G. (2021). Calibrating mini-mental state
 examination scores to predict misdiagnosed dementia patients. *Applied Sciences* 11, 8055
- Wang, J.-H., Wu, Y.-J., Tee, B. L., and Lo, R. Y. (2018). Medical comorbidity in alzheimer's disease: a
 nested case-control study. *Journal of Alzheimer's disease* 63, 773–781
- Wysocki, M., Luo, X., Schmeidler, J., Dahlman, K., Lesser, G. T., Grossman, H., et al. (2012). Hypertension
 is associated with cognitive decline in elderly people at high risk for dementia. *The American journal of geriatric psychiatry* 20, 179–187
- Xia, Y., Yassi, N., Raniga, P., Bourgeat, P., Desmond, P., Doecke, J., et al. (2020). Comorbidity of
 cerebrovascular and alzheimer's disease in aging. *Journal of Alzheimer's Disease* 78, 321–334
- Xu, W., Tan, L., Wang, H.-F., Tan, M.-S., Tan, L., Li, J.-Q., et al. (2016). Education and risk of dementia:
 dose-response meta-analysis of prospective cohort studies. *Molecular neurobiology* 53, 3113–3123
- Yen, F.-S., Wei, J. C.-C., Yip, H.-T., Hwu, C.-M., and Hsu, C.-C. (2022). Diabetes, hypertension, and the
 risk of dementia. *Journal of Alzheimer's Disease* 89, 323–333
- Zeng, N., Qiu, H., Wang, Z., Liu, W., Zhang, H., and Li, Y. (2018). A new switching-delayed-pso-based
 optimized svm algorithm for diagnosis of alzheimer's disease. *Neurocomputing* 320, 195–202
- 567 Zhu, F., Panwar, B., Dodge, H. H., Li, H., Hampstead, B. M., Albin, R. L., et al. (2016). Compass: A
- computational model to predict changes in mmse scores 24-months after initial assessment of alzheimer's
 disease. *Scientific reports* 6, 34567